Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24

Tao Yu1, Shucheng Gan1, Qingchen Zhu1

  • 1CAS Key Laboratory of Tissue Microenvironment and Tumor, Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine & Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.

Nature Communications
|September 27, 2019
PubMed

Insights

Acetylation of Signal transducer and activator of transcription 6 (Stat6) by CREB-binding protein (CBP) suppresses M2 macrophage polarization. Trim24 facilitates this acetylation, impacting antitumor immunity and tumor microenvironments.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Signal transducer and activator of transcription 6 (Stat6) is a key regulator of macrophage M2 polarization.
  • The precise mechanisms by which Stat6 activity is fine-tuned remain incompletely understood.

Purpose of the Study:

  • To elucidate the regulatory mechanisms controlling Stat6 activity during macrophage polarization.
  • To investigate the role of Stat6 acetylation in macrophage M2 polarization and its implications for antitumor immunity.

Main Methods:

  • Macrophage activation and polarization assays in mouse and human cells.
  • Biochemical analyses including acetylation and ubiquitination assays.
  • Western blotting and immunoprecipitation to study protein interactions.
  • Gene expression analysis to assess TRIM24 and other relevant markers.

Main Results:

  • Lysine 383 (Lys383) acetylation of Stat6 by CREB-binding protein (CBP) suppresses M2 polarization.
  • The E3 ligase Trim24 promotes Stat6 acetylation by catalyzing CBP ubiquitination, enhancing CBP recruitment to Stat6.
  • Loss of Trim24 leads to reduced Stat6 acetylation, increased M2 polarization, and potentially impaired antitumor responses.
  • Stat6 suppresses TRIM24 expression in M2 macrophages, contributing to an immunosuppressive tumor niche.

Conclusions:

  • Stat6 acetylation is an essential negative regulatory mechanism controlling macrophage M2 polarization.
  • The Trim24-CBP-Stat6 axis represents a novel pathway for modulating macrophage phenotypes.
  • Targeting this pathway could offer therapeutic strategies for enhancing antitumor immunity.